Latest News and Press Releases

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) -  Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...

SAN DIEGO, CA--(Marketwire - May 21, 2010) -  Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 29, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...

SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - April 26, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHLD), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...

NEW CANAAN, CT--(Marketwire - April 20, 2010) -  Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today...

NEW CANAAN, CT--(Marketwire - March 31, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) (NASDAQ: MSHLD), a specialist oncology company focusing on the clinical development of novel anti-cancer...

SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced that Christopher Naughton had resigned as a member of the Board of Directors effective February 5,...

NEW CANAAN, CT--(Marketwire - January 21, 2010) - The Board of Directors of Marshall Edwards, Inc. today advised that analysis of tumor response data from the OVATURE trial will be performed in the...

SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - December 1, 2009) - Novogen Limited advises that CEO and Managing Director Christopher Naughton will cease his employment with the Company from...